Medical & Surgical
- Cardiology
- Oncology
- Neurology
- Orthopedics
- Gastroenterology
- Urology
- Neurosurgery
- Women’s Health
- Rheumatology
- Hematology
- Pulmonology
- Wound Management
- Anesthesiology
- Interventional Radiology
Red House B2B Marketing is a B2B healthcare marketing agency that has spent 25+ years reaching providers, payers, and medical device and pharmaceutical & life sciences decision-makers. We help Healthcare organizations turn complex value into clear market advantage—and guide diverse buying committees from first signal to confident decision.
25+ years reaching providers, payers, medical device and pharmaceutical & life sciences decision-makers.
Specific experience across the care models, specialties and technologies that shape Healthcare decisions.
This isn’t surface-level targeting. It’s fluency in how each audience evaluates and adopts solutions.
“You can't personalize under HIPAA.” We do it every day.
Market research, audience strategy, positioning, portfolio architecture, go-to-market planning and market access and stakeholder engagement strategy.
Campaigns, content, digital experiences, media and account-based programs built for real buying groups — including service line–aligned campaigns (cardiology, oncology, orthopedics) and physician engagement and influence strategies.
Measurement, optimization, audience insight and a learning rhythm that compounds over time.
November 2026 edition
A concise, human-reviewed monthly read on the structural shifts changing how Healthcare markets move.
Payers are moving the same way, with 54% planning to buy in most cases, up from 31% in 2024, and AI budgets rising on both sides.
The barrier is not appetite. Providers citing workflow integration as a concern jumped from 31% in 2024 to 82% in 2026, and most buyers on both sides want measurable ROI within a year.
For healthcare sellers, the competitive set is no longer the internal build — it is the other vendor whose integration story is easier to believe. Lead with workflow fit: where the tool sits in the clinical or administrative day, what it displaces, and how change management is handled, because half of payers now name that as a concern. Put the one-year ROI measure in the proposal, defined the buyer's way — cost savings for payers, revenue for providers. A product that needs the customer to build around it loses to one that arrives already fitted.
Site-neutral payment and 340B policy are still evolving at the same time, and systems are already re-sequencing major builds — proving one initiative before funding the next, and scaling some projects back rather than cancelling them.
Waiting for clarity is not the plan; deciding under uncertainty is.
For sellers, the budget conversation has changed shape. Proposals that assume a stable policy environment will stall; proposals built for scenarios — phased commitments, flexibility if coverage shifts, and value that holds under a thinner payer mix — match how buyers are actually planning. Bring the re-sequencing offer yourself: a first step that proves value before the full commitment, priced so a CFO can fund it inside an uncertain year. Sellers who help a system protect strategic investment through the uncertainty will be in the budget that survives it.
The gap is mainly in clinical tools, not operational ones, and the authors link it to acquisition capital flowing toward technology that earns revenue.
The barriers differ by owner, too: nonprofits cite cost and resources most, while private equity-owned hospitals cite staff training.
For healthcare sellers, ownership is now a segmentation variable as real as size or region. The same AI pitch lands differently by owner: a capital-backed clinical case for PE-owned systems, a cost-and-capacity case for nonprofits, and a first-step case for the for-profit hospitals that have barely started. Account research should record the owner and the barrier that owner reports — training support may matter more than price in one segment, and a funded implementation more than features in another. One national message will miss all three.
Two migrated engagements from the Red House case library — the client, the work and the outcome, as each case was reported.
A global diagnostic device and service provider whose employer solutions span wellness, condition management and case management. They needed best practices for content marketing and demand generation — and, lacking experience in both, needed benchmarks to guide future lead forecasting.
A provider of healthcare solutions to health systems and group practices — telehealth, medical imaging and information management, health information exchange and mobile health. With a recent telehealth launch, they needed awareness, qualified leads and a pipeline to meet short-term sales goals.
It markets to the organizations and decision-makers inside healthcare — hospitals and health systems, payers, physician groups, and the companies that sell to them — rather than to patients. The work is brand and messaging, demand generation, account-based marketing and content built for long, committee-driven buying decisions.
Consumer healthcare marketing speaks to patients choosing care. B2B healthcare marketing speaks to executives, clinicians and operators choosing vendors, technology and partners — decisions made by committees, over months, under regulatory scrutiny. The messages, channels and proof points are entirely different.
Diagnostics and laboratory services, healthcare distribution and supply chain, healthcare IT and digital health, health plans and payers, home-based care, hospitals and health systems, medical devices and equipment, pharmaceuticals and life sciences, physician groups and practice management, and value-based care.
Healthcare buying is regulated, technical and relationship-driven, and generalist messaging misses how decisions actually get made. Red House has spent 25+ years reaching providers, payers, and medical device and pharmaceutical & life sciences decision-makers, and that depth shapes the positioning and demand programs it builds.